Review



boc mlf  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Tocris boc mlf
    ELISA assays in the supernatant of the axon chambers. NTC: no-treatment control; a-TLR+PA: the axon chamber pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA: the axon chamber pre-treated with Fpr1 <t>antagonist,</t> <t>Boc-MLF</t> (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: the axon chamber pre-treated with both LPS-RS Ultrapure (20 µg/mL) and Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.
    Boc Mlf, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/bio_rxiv__64898__2026__03__30__715374-171-22-23
    Average 93 stars, based on 21 article reviews
    boc mlf - by Bioz Stars, 2026-09
    93/100 stars

    Images

    1) Product Images from "The miR-183/96/182 Cluster Regulates Trigeminal Ganglion Sensory Neurons’ Response to Pseudomonas aeruginosa Infection"

    Article Title: The miR-183/96/182 Cluster Regulates Trigeminal Ganglion Sensory Neurons’ Response to Pseudomonas aeruginosa Infection

    Journal: bioRxiv

    doi: 10.64898/2026.03.30.715374

    ELISA assays in the supernatant of the axon chambers. NTC: no-treatment control; a-TLR+PA: the axon chamber pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA: the axon chamber pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: the axon chamber pre-treated with both LPS-RS Ultrapure (20 µg/mL) and Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.
    Figure Legend Snippet: ELISA assays in the supernatant of the axon chambers. NTC: no-treatment control; a-TLR+PA: the axon chamber pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA: the axon chamber pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: the axon chamber pre-treated with both LPS-RS Ultrapure (20 µg/mL) and Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Control, Infection, Comparison

    ELISA assays in the cell lysates of the soma chambers. NTC: no treatment control; a-TLR+PA: axon chambers pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA:, the axon chambers pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: axon chambers pre-treated with LPS-RS Ultrapure (20 µg/mL) and Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.
    Figure Legend Snippet: ELISA assays in the cell lysates of the soma chambers. NTC: no treatment control; a-TLR+PA: axon chambers pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA:, the axon chambers pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: axon chambers pre-treated with LPS-RS Ultrapure (20 µg/mL) and Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Control, Infection, Comparison

    Related Articles

    Sequencing:

    Article Title: Cathelicidin-related antimicrobial peptide promotes neuroinflammation through astrocyte-microglia communication in experimental autoimmune encephalomyelitis.
    Article Snippet: Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu, Republic of Korea Division of Endocrinology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA Brain Science Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea School of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Kyungpook National University, Daegu, Republic of Korea Brain Science and Engineering Institute, Kyungpook National University, Daegu, Republic of Korea

    other:

    Article Title: Identification of anti-resorptive GPCRs by high-content imaging in human osteoclasts
    Article Snippet: , Boc-MLF , Formyl peptide receptor 1 (FPR1) , 5 μM , Tocris, 3730/1.

    Article Title: Pyridazinones and Structurally Related Derivatives with Anti-Inflammatory Activity
    Article Snippet: Cmpd43 (TC-FPR 43) and Boc-MLF were purchased from Tocris Biosciences (Bristol, UK).

    Infection:

    Article Title: The miR-183/96/182 Cluster Regulates Trigeminal Ganglion Sensory Neurons’ Response to Pseudomonas aeruginosa Infection
    Article Snippet: .. To test this hypothesis, we pre-treated the neurites in the axon chambers with a TLR4-specific antagonist, TLR4-RS (InVivoGen), and/or a FPR1-specific antagonist, Boc-MLF (TOCRIS) 2 hours before PA infection. ..

    DNA Extraction:

    Article Title: A Critical Role of Formyl Peptide Receptors in Host Defense against Escherichia coli
    Article Snippet: Mouse experiments were approved by Animal Care and Use Committee of the National Cancer Institute and the National Institute of Allergy and Infectious Diseases and performed in accordance with the procedures outlined in the “Guide for Care and Use of Laboratory Animals” (National Research Council, 1996, National Academy Press, Washington, D.C.). .. Rat anti-mouse Ly6G and 6-diamidino-2-phenylindole Abs were obtained from Becton-Dickinson (Franklin Lakes, NJ); goat anti-Rat Ig-FITC Abs were obtained from eBioscience (San Diego, CA); Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit was from Invitrogen (Eugene, OR); rat anti-mouse Abs against p-p38 MAPK (Thr 180 /Tyr 182 ), p38, p-ERK1/2 (Thr 202 /Tyr 204 ), ERK1/2, pAkt, Akt, IkBα, GAPDH, and HRP-linked anti-rabbit IgG Abs were from Cell Signaling Technology (Beverly, MA); FITC isomer 1 and poly-lysine were from Sigma-Aldrich (St. Louis, MO); Boc-MLF, WRW4, Boc-2, fMLF, and SDF1α (CXCL12) were from Tocris (Ellisville, MO); the p38 inhibitor SB203580, ERK1/2 inhibitor PD98059, Akt inhibitor Mk2206, and IκB inhibitor PDTC were from Abcam (Cambridge, MA); Microbial DNA Isolation Kit was from Thermo Fisher Scientific (Waltham, MA); DNeasy UltraClean Microbial Kit was from Qiagen (Germantown, MD). ..



    Similar Products

    human frp2 receptor inhibitor boc mlf  (MedChemExpress)
    93
    MedChemExpress human frp2 receptor inhibitor boc mlf
    Human Frp2 Receptor Inhibitor Boc Mlf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/pm41349809-58-1-11
    Average 93 stars, based on 1 article reviews
    human frp2 receptor inhibitor boc mlf - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    boc mlf  (Tocris)
    93
    Tocris boc mlf
    ELISA assays in the supernatant of the axon chambers. NTC: no-treatment control; a-TLR+PA: the axon chamber pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA: the axon chamber pre-treated with Fpr1 <t>antagonist,</t> <t>Boc-MLF</t> (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: the axon chamber pre-treated with both LPS-RS Ultrapure (20 µg/mL) and Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.
    Boc Mlf, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/bio_rxiv__64898__2026__03__30__715374-171-22-23
    Average 93 stars, based on 1 article reviews
    boc mlf - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    fpr1 receptor  (Tocris)
    93
    Tocris fpr1 receptor
    Fig. 4. Impact of Selected Receptor Antagonists on RAW 264.7 cells: Immunological Activation Markers, TNFα Secretion, and NO Production. A) RAW 264.7 cells were pretreated for 30 min with Boc-MLF, AMG 487 or LPS-RS, which are inhibitors of the receptor <t>FPR1,</t> CXCR3 and TLR4, respectively, before addition of gliadin (G). Following 24 h of incubation, the cells were stained for surface expression of CD11b, ICAM-1, MHC-II, CD86, CD40 and CD80 and analyzed by flow cytometry. Mean fluorescence intensity was tested against control cells. No inhibitor tested abolished the gliadin response. The histograms show the MFI results from repre sentative experiments with unstained cells (grey) and cells treated with enzyme control (blue), gliadin (green) or LPS (orange), stained with antibodies at optimal dilutions. The Y-axis shows the cell count as percentage of maximum, and the X-axis (biexponential) shows fluorescence intensity. B) TNF-α production was measured by ELISA and normalized to the levels of untreated cells. Likewise, no inhibitor reduced TNF-α production. C) NO production is shown relative to the level for untreated cells. Gliadin did not stimulate NO production. Data represent six independent experiments and were analyzed by one-way ANOVA (multiple comparison test) and statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars indicate the standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
    Fpr1 Receptor, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/pm40517557-55-5-13
    Average 93 stars, based on 1 article reviews
    fpr1 receptor - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    boc fmlp boc mlf  (Tocris)
    93
    Tocris boc fmlp boc mlf
    Fig. 4. Impact of Selected Receptor Antagonists on RAW 264.7 cells: Immunological Activation Markers, TNFα Secretion, and NO Production. A) RAW 264.7 cells were pretreated for 30 min with Boc-MLF, AMG 487 or LPS-RS, which are inhibitors of the receptor <t>FPR1,</t> CXCR3 and TLR4, respectively, before addition of gliadin (G). Following 24 h of incubation, the cells were stained for surface expression of CD11b, ICAM-1, MHC-II, CD86, CD40 and CD80 and analyzed by flow cytometry. Mean fluorescence intensity was tested against control cells. No inhibitor tested abolished the gliadin response. The histograms show the MFI results from repre sentative experiments with unstained cells (grey) and cells treated with enzyme control (blue), gliadin (green) or LPS (orange), stained with antibodies at optimal dilutions. The Y-axis shows the cell count as percentage of maximum, and the X-axis (biexponential) shows fluorescence intensity. B) TNF-α production was measured by ELISA and normalized to the levels of untreated cells. Likewise, no inhibitor reduced TNF-α production. C) NO production is shown relative to the level for untreated cells. Gliadin did not stimulate NO production. Data represent six independent experiments and were analyzed by one-way ANOVA (multiple comparison test) and statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars indicate the standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
    Boc Fmlp Boc Mlf, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/pm40517557-55-0-13
    Average 93 stars, based on 1 article reviews
    boc fmlp boc mlf - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    5256 10 boc mlf formyl peptide receptor 1  (Tocris)
    93
    Tocris 5256 10 boc mlf formyl peptide receptor 1
    Fig. 4. Impact of Selected Receptor Antagonists on RAW 264.7 cells: Immunological Activation Markers, TNFα Secretion, and NO Production. A) RAW 264.7 cells were pretreated for 30 min with Boc-MLF, AMG 487 or LPS-RS, which are inhibitors of the receptor <t>FPR1,</t> CXCR3 and TLR4, respectively, before addition of gliadin (G). Following 24 h of incubation, the cells were stained for surface expression of CD11b, ICAM-1, MHC-II, CD86, CD40 and CD80 and analyzed by flow cytometry. Mean fluorescence intensity was tested against control cells. No inhibitor tested abolished the gliadin response. The histograms show the MFI results from repre sentative experiments with unstained cells (grey) and cells treated with enzyme control (blue), gliadin (green) or LPS (orange), stained with antibodies at optimal dilutions. The Y-axis shows the cell count as percentage of maximum, and the X-axis (biexponential) shows fluorescence intensity. B) TNF-α production was measured by ELISA and normalized to the levels of untreated cells. Likewise, no inhibitor reduced TNF-α production. C) NO production is shown relative to the level for untreated cells. Gliadin did not stimulate NO production. Data represent six independent experiments and were analyzed by one-way ANOVA (multiple comparison test) and statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars indicate the standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
    5256 10 Boc Mlf Formyl Peptide Receptor 1, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/10__1530_slash_jme___24___0143-294-108-117
    Average 93 stars, based on 1 article reviews
    5256 10 boc mlf formyl peptide receptor 1 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    boc‐mlf  (GlpBio Technology Inc)
    90
    GlpBio Technology Inc boc‐mlf
    Fig. 4. Impact of Selected Receptor Antagonists on RAW 264.7 cells: Immunological Activation Markers, TNFα Secretion, and NO Production. A) RAW 264.7 cells were pretreated for 30 min with Boc-MLF, AMG 487 or LPS-RS, which are inhibitors of the receptor <t>FPR1,</t> CXCR3 and TLR4, respectively, before addition of gliadin (G). Following 24 h of incubation, the cells were stained for surface expression of CD11b, ICAM-1, MHC-II, CD86, CD40 and CD80 and analyzed by flow cytometry. Mean fluorescence intensity was tested against control cells. No inhibitor tested abolished the gliadin response. The histograms show the MFI results from repre sentative experiments with unstained cells (grey) and cells treated with enzyme control (blue), gliadin (green) or LPS (orange), stained with antibodies at optimal dilutions. The Y-axis shows the cell count as percentage of maximum, and the X-axis (biexponential) shows fluorescence intensity. B) TNF-α production was measured by ELISA and normalized to the levels of untreated cells. Likewise, no inhibitor reduced TNF-α production. C) NO production is shown relative to the level for untreated cells. Gliadin did not stimulate NO production. Data represent six independent experiments and were analyzed by one-way ANOVA (multiple comparison test) and statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars indicate the standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
    Boc‐Mlf, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/boc+mlf/pmc11659116-61-3-7
    Average 90 stars, based on 1 article reviews
    boc‐mlf - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    boc mlf  (R&D Systems)
    94
    R&D Systems boc mlf
    Fig. 4. Impact of Selected Receptor Antagonists on RAW 264.7 cells: Immunological Activation Markers, TNFα Secretion, and NO Production. A) RAW 264.7 cells were pretreated for 30 min with Boc-MLF, AMG 487 or LPS-RS, which are inhibitors of the receptor <t>FPR1,</t> CXCR3 and TLR4, respectively, before addition of gliadin (G). Following 24 h of incubation, the cells were stained for surface expression of CD11b, ICAM-1, MHC-II, CD86, CD40 and CD80 and analyzed by flow cytometry. Mean fluorescence intensity was tested against control cells. No inhibitor tested abolished the gliadin response. The histograms show the MFI results from repre sentative experiments with unstained cells (grey) and cells treated with enzyme control (blue), gliadin (green) or LPS (orange), stained with antibodies at optimal dilutions. The Y-axis shows the cell count as percentage of maximum, and the X-axis (biexponential) shows fluorescence intensity. B) TNF-α production was measured by ELISA and normalized to the levels of untreated cells. Likewise, no inhibitor reduced TNF-α production. C) NO production is shown relative to the level for untreated cells. Gliadin did not stimulate NO production. Data represent six independent experiments and were analyzed by one-way ANOVA (multiple comparison test) and statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars indicate the standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
    Boc Mlf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/pmc11016758-326-31-54
    Average 94 stars, based on 1 article reviews
    boc mlf - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    103473a  (MedChemExpress)
    93
    MedChemExpress 103473a

    103473a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/boc+mlf/Boc-MLF/pmc10587614-49-5-3
    Average 93 stars, based on 1 article reviews
    103473a - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ELISA assays in the supernatant of the axon chambers. NTC: no-treatment control; a-TLR+PA: the axon chamber pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA: the axon chamber pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: the axon chamber pre-treated with both LPS-RS Ultrapure (20 µg/mL) and Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.

    Journal: bioRxiv

    Article Title: The miR-183/96/182 Cluster Regulates Trigeminal Ganglion Sensory Neurons’ Response to Pseudomonas aeruginosa Infection

    doi: 10.64898/2026.03.30.715374

    Figure Lengend Snippet: ELISA assays in the supernatant of the axon chambers. NTC: no-treatment control; a-TLR+PA: the axon chamber pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA: the axon chamber pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: the axon chamber pre-treated with both LPS-RS Ultrapure (20 µg/mL) and Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.

    Article Snippet: To test this hypothesis, we pre-treated the neurites in the axon chambers with a TLR4-specific antagonist, TLR4-RS (InVivoGen), and/or a FPR1-specific antagonist, Boc-MLF (TOCRIS) 2 hours before PA infection.

    Techniques: Enzyme-linked Immunosorbent Assay, Control, Infection, Comparison

    ELISA assays in the cell lysates of the soma chambers. NTC: no treatment control; a-TLR+PA: axon chambers pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA:, the axon chambers pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: axon chambers pre-treated with LPS-RS Ultrapure (20 µg/mL) and Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.

    Journal: bioRxiv

    Article Title: The miR-183/96/182 Cluster Regulates Trigeminal Ganglion Sensory Neurons’ Response to Pseudomonas aeruginosa Infection

    doi: 10.64898/2026.03.30.715374

    Figure Lengend Snippet: ELISA assays in the cell lysates of the soma chambers. NTC: no treatment control; a-TLR+PA: axon chambers pretreated with TLR4-specific antagonist, LPS-RS Ultrapure (20 µg/mL) 2 hours before PA infection; a-Fpr+PA:, the axon chambers pre-treated with Fpr1 antagonist, Boc-MLF (2 µg/mL) 2 hours before PA infection; a-TLR/Fpr+PA: axon chambers pre-treated with LPS-RS Ultrapure (20 µg/mL) and Boc-MLF (2 µg/mL) 2 hours before PA infection. *: p<0.05, **: p<0.01, ***:p<0.001 by one-way ANOVA of multiple sample comparison with Bonferroni post hoc test. #: p<0.05, ##: p<0.01, ###: p<0.001 by Student’s t test.

    Article Snippet: To test this hypothesis, we pre-treated the neurites in the axon chambers with a TLR4-specific antagonist, TLR4-RS (InVivoGen), and/or a FPR1-specific antagonist, Boc-MLF (TOCRIS) 2 hours before PA infection.

    Techniques: Enzyme-linked Immunosorbent Assay, Control, Infection, Comparison

    Fig. 4. Impact of Selected Receptor Antagonists on RAW 264.7 cells: Immunological Activation Markers, TNFα Secretion, and NO Production. A) RAW 264.7 cells were pretreated for 30 min with Boc-MLF, AMG 487 or LPS-RS, which are inhibitors of the receptor FPR1, CXCR3 and TLR4, respectively, before addition of gliadin (G). Following 24 h of incubation, the cells were stained for surface expression of CD11b, ICAM-1, MHC-II, CD86, CD40 and CD80 and analyzed by flow cytometry. Mean fluorescence intensity was tested against control cells. No inhibitor tested abolished the gliadin response. The histograms show the MFI results from repre sentative experiments with unstained cells (grey) and cells treated with enzyme control (blue), gliadin (green) or LPS (orange), stained with antibodies at optimal dilutions. The Y-axis shows the cell count as percentage of maximum, and the X-axis (biexponential) shows fluorescence intensity. B) TNF-α production was measured by ELISA and normalized to the levels of untreated cells. Likewise, no inhibitor reduced TNF-α production. C) NO production is shown relative to the level for untreated cells. Gliadin did not stimulate NO production. Data represent six independent experiments and were analyzed by one-way ANOVA (multiple comparison test) and statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars indicate the standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Journal: Cellular immunology

    Article Title: Gliadin amplifies the macrophage response triggered by stressed beta cells.

    doi: 10.1016/j.cellimm.2025.104989

    Figure Lengend Snippet: Fig. 4. Impact of Selected Receptor Antagonists on RAW 264.7 cells: Immunological Activation Markers, TNFα Secretion, and NO Production. A) RAW 264.7 cells were pretreated for 30 min with Boc-MLF, AMG 487 or LPS-RS, which are inhibitors of the receptor FPR1, CXCR3 and TLR4, respectively, before addition of gliadin (G). Following 24 h of incubation, the cells were stained for surface expression of CD11b, ICAM-1, MHC-II, CD86, CD40 and CD80 and analyzed by flow cytometry. Mean fluorescence intensity was tested against control cells. No inhibitor tested abolished the gliadin response. The histograms show the MFI results from repre sentative experiments with unstained cells (grey) and cells treated with enzyme control (blue), gliadin (green) or LPS (orange), stained with antibodies at optimal dilutions. The Y-axis shows the cell count as percentage of maximum, and the X-axis (biexponential) shows fluorescence intensity. B) TNF-α production was measured by ELISA and normalized to the levels of untreated cells. Likewise, no inhibitor reduced TNF-α production. C) NO production is shown relative to the level for untreated cells. Gliadin did not stimulate NO production. Data represent six independent experiments and were analyzed by one-way ANOVA (multiple comparison test) and statistical significance is indicated as * P < 0.05, ** P < 0.01, *** P < 0.001. Error bars indicate the standard deviation. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Article Snippet: BOC fMLP (Boc-MLF) inhibits the FPR1 receptor (10 μM, EC50 = 0.63 μM, Tocris).

    Techniques: Activation Assay, Incubation, Staining, Expressing, Flow Cytometry, Fluorescence, Control, Cell Counting, Enzyme-linked Immunosorbent Assay, Comparison, Standard Deviation

    Journal: iScience

    Article Title: Annexin A1 exerts analgesic effect in a mouse model of medication overuse headache

    doi: 10.1016/j.isci.2023.108153

    Figure Lengend Snippet:

    Article Snippet: Boc-MLF TFA , MedChemExpress , CatHY-103473A.

    Techniques: Recombinant, cDNA Synthesis, SYBR Green Assay, Lysis, Protease Inhibitor, Bicinchoninic Acid Protein Assay, Western Blot, Software, Microscopy, Real-time Polymerase Chain Reaction, Imaging, Injection